Mark Connolly

The Street has a lot of faith in Sarepta Therapeutics, Inc. (NASDAQ: SRPT). The biotech firm notched its 20th bullish rating Thursday to further neutralize a lone Hold. The Rating Credit Suisse analysts Martin Auster, Mark Connolly and Tiago Fauth initiated coverage on Sarepta with an Outperform...